clinical trial · NCT05050942
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Gastro-enteropancreatic Neuroendocrine TumorCAM2029Octreotide LARLanreotide ATG
brief summary
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
started
Oct 22, 2021
primary completion
Jul 1, 2026
completion
Jul 1, 2028
last updated
Nov 6, 2025
official title
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol